Stoke Therapeutics Inc

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)